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In all biological systems, protein amount is a function of the rate of production and clearance.
The speed of a response to a disturbance in protein homeostasis is determined by turnover
rate. Quantifying alterations in protein synthesis and clearance rates is vital to understanding
disease pathogenesis (e.g., aging, inflammation). No methods currently exist for quantifying
production and clearance rates of low-abundance (femtomole) proteins in vivo. We describe a
novel, mass spectrometry–based method for quantitating low-abundance protein synthesis
and clearance rates in vitro and in vivo in animals and humans. The utility of this method is
demonstrated with amyloid- (A), an important low-abundance protein involved in Alzhei-
mer’s disease pathogenesis. We used in vivo stable isotope labeling, immunoprecipitation of
A from cerebrospinal fluid, and quantitative liquid chromatography electrospray-ionization
tandem mass spectrometry (LC-ESI-tandem MS) to quantify human A protein production
and clearance rates. The method is sensitive and specific for stable isotope-labeled amino acid
incorporation into CNS A (1% accuracy). This in vivo method can be used to identify
pathophysiologic changes in protein metabolism and may serve as a biomarker for monitoring
disease risk, progression, or response to novel therapeutic agents. The technique is adaptable
to other macromolecules, such as carbohydrates or lipids. (J Am Soc Mass Spectrom 2007, 18,
997–1006) © 2007 American Society for Mass SpectrometryRecent advances in mass spectrometry have led tosignificant improvements in the types and com-plexity of samples that can be analyzed, sensi-
tivity of detection, and amount of structural informa-
tion that can be obtained. These advances have been
combined with chemical and isotope labeling tech-
niques that allow for the comparison of protein
amounts under different experimental conditions [1, 2].
SILAC (stable isotope labeling by amino acids in cell
culture), a technique used to label proteins expressed in
vitro by incubating cells with stable isotope-labeled
amino acids, provides an excellent non-radioactive
method for labeling proteins during production that
does not alter chemical or biologic properties [3]. This in
vitro labeling method has been used with liquid chro-
matography mass spectrometry (LC-MS) to obtain mea-
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doi:10.1016/j.jasms.2007.02.009surements of relative and total amounts of low-abun-
dance proteins. In addition, stable isotope labeling has
also been used in vivo to produce highly enriched
protein/peptide internal standards for proteomic anal-
ysis [4].
Techniques to measure stable isotope incorporation
in vivo have used gas chromatography mass spectrom-
etry (GC-MS), which has high mass resolution, but low
sensitivity, and so requires a relatively large amount of
protein for quantitative analysis. In addition, GC-MS
quantifies stable isotope enrichment of amino acids and
does not provide specific identification of the source
proteins/peptides. Human plasma and skeletal muscle
protein synthesis rates have been quantified using this
method, although only the most abundant proteins
have been studied [5]. Most proteins in biologic samples
are present in less than nanomole per milliliter quanti-
ties and approach the limit of detection for most GC-MS
systems.
We describe a novel method for quantifying produc-
tion and clearance rates for low-abundance (femtomole)
proteins using tandem mass spectrometry (MS/MS). By
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than the parent MS ion, significantly higher signal-to-
noise ratio can be achieved. This allows for isotope ratio
quantitation for low-abundance proteins/peptides that
would not be detectable by standard MS analysis. The
technique uses in vivo rates of stable isotope-labeled
amino acid incorporation and tandem MS quantitation,
so that protein production and clearance rates are
calculated while peptide sequence information is ob-
tained for positive protein identification.
Protein production and clearance rates are important
parameters that are tightly regulated under normal
physiologic and pathophysiologic conditions [6 –11].
Certain disease states are characterized by disturbances
in protein production, accumulation, or clearance. For
example, CNS diseases such as Alzheimer’s disease,
frontal temporal dementia, Huntington disease, and
Creutzfeldt–Jakob disease are associated with distur-
bance in A, tau, huntingtin, and prion proteins, respec-
tively. The amyloid hypothesis proposes that distur-
bances in the metabolism of amyloid- (A) [12] causes
Alzheimer disease (AD). A is normally made predom-
inantly by neurons and is present in cerebrospinal fluid
and blood, although no methods were available to
quantify A synthesis or clearance rates in humans. To
address critical questions about underlying AD patho-
genesis and Ametabolism in humans, we developed a
method to quantify A fractional synthesis rate (FSR)
and fractional clearance rate (FCR) in vivo in the CNS of
humans. The findings indicate that reproducible rates
of A synthesis and clearance can be quantified in
normal humans by administering stable isotope-labeled
amino acids (13C6-leucine), sampling CSF, and using
LC-ESI-tandem MS to quantify the amount and kinetics
of 13C6-leucine labeling in A [13].
The current method was developed to measure the
production and clearance rate of A in humans, but is
applicable to proteins being produced in vitro or in vivo
because all proteins are labeled simultaneously. This
communication describes the methodology to perform
quantitative measurements of proteins by stable isotope
labeling and tandem mass spectrometry (SILT) and
expands the technique to use two stable isotope-labeled
amino acids to measure the production rate sequen-






13C6) were obtained from Cambridge Isotope Laborato-
ries (Andover, MA, USA). M266 antibody against A
was provided by Eli Lilly (Indianapolis, IN, USA).
CNBr-activated sepharose 4B beads were obtained from
Amersham Biosciences (Piscataway, NJ, USA). Formic
acid (98%) and ammonium bicarbonate (ultra 99.5%,)
were obtained from Fluka (AG, Buchs, Switzerland).
Fetal bovine serum (FBS) and Dulbecco’s modifiedessential media (DMEM), with and without leucine,
were obtained from the Washington University Tissue
Culture Support Center. Hygromycin B, Streptomyces
sp. #400051 was obtained from EMD Biosciences (San
Diego, CA, USA) and made in 100 stock of 426 mg/mL;
Blasticidin S, Hydrochloride (Streptomyces griseochromo-
genes #203350) obtained from CalBioChem (San Diego,
CA, USA) and made in 100 stocks of 10 mg/mL.
Sequence grade modified trypsin was obtained from Pro-
mega (Madison, WI, USA).
Cell Culture and In Vitro Labeling
Human neuroglioma cells that produce A [14] were
grown in the presence of 13C6-leucine or unlabeled
leucine. The unlabeled media was DMEM 10% FBS
antibiotics. The labeled media was leucine-free
DMEM  105 mg/L 13C6-leucine  3 kDa dialyzed
FBS antibiotics. Media was collected every 24–48 h of
incubation to obtain highly labeled or unlabeled A.
The media was pooled separately and stored at20 °C.
A concentration in each pool was determined by
ELISA [15]. Using serial, volumetric dilution of labeled
and unlabeled media, 13C6-A enrichment standards of
20, 10, 5, 2.5, 1.25, and 0% labeled media were made,
aliquoted, and stored at 80 °C.
Amyloid- Immunoprecipitation
Antibody beads were prepared by covalently binding
m266 antibody to CNBr sepharose beads according to
the manufacturer’s protocol at a concentration of 10
mg/mL m266 antibody. The antibody beads were
stored at 4 °C in a 50% slurry of PBS 0.02% azide.
The immunoprecipitation mixture was 250 L of 5
RIPA, 12.5 L of 100 protease inhibitors, and 30 L of
antibody-bead slurry added to 1 mL of sample in an
Eppendorf micro-centrifuge tube which was rotated
overnight at 4 °C. The beads were rinsed once with 1
RIPA and twice with 1 ammonium bicarbonate. They
were aspirated dry after the final rinse and A was
eluted off the antibody–bead complex using 30 L of
100% formic acid. After centrifuging the beads again,
the formic acid supernatant was transferred to a new
Eppendorf tube and evaporated in a Savant speed-vac
(model AES2010) for 15 min at low rate (ambient
temperature) with radiant cover and full vacuum, fol-
lowed by 30 min at medium rate (43 °C) with radiant
cover and full vacuum. The sample was reconstituted in
5 L of acetonitrile and 20 L of 25 mM ammonium
bicarbonate, pH 8.0. The sample was digested with 400
ng sequence grade trypsin and incubated at 37 °C for
16 h.
Liquid Chromatography/Mass Spectrometry
LCQ ESI-tandem MS was performed on a Thermo-
Finnigan (San Jose, CA, USA) LCQ-DECA equipped
with an electrospray ionization source. The LCQ-DECA
was operated in the positive ion mode using a spray
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capillary temperature at 200 °C. The instrument settings
were set for ion-specific analysis at full MS/MS mode at
28% normal collisional energy of the precursor MS ions
at m/z  663.5 and 666.5 (doubly charged [M2H]2).
Mass spectra were collected over a 38-min period after
a 10-min delay time.
The liquid chromatography for LCQ analysis was
carried out on a Waters (Milford, MA, USA) micro-
capillary liquid chromatography system with auto-
injector interfaced to the mass spectrometer. Samples
were chilled at 5 °C until injection. A 5-L aliquot of
each sample was injected on-column to a Vydac C18
capillary column (0.3  150 mm MS 5 m). The HPLC
gradient of 0–90% B (0–5 min at 0% B, 5–25 min to 50%
B, 25–30 min to 90% B, 30–33 min at 90% B, 33–35 min
to 0% B, 35–40 min at 0% B) over 40 min (A  0.1%
formic acid in water, B  0.1% formic acid in 80%
acetonitrile/20% water) at a flow rate of 6 L/min was
used.
LTQ experiments were performed on a Thermo-
Finnigan LTQ equipped with a New Objective
(Woburn, MA, USA) nanoflow electrospray ionization
source. Sample injection and LC gradients were con-
trolled by an Eksigent 2D-LC nanoflow pump operating
in a 1D mode. Samples were chilled at 5 °C until
injection. A 5-L aliquot of each sample was injected
on-column to a New Objective biobasic picofrit column
(75 m  150 mm). The HPLC gradient used was:
5–95% B (0–5 min at 5% B, 5–45 min to 50% B, 45–50
min to 90% B, 50–60 min to 5% B), over 60 min (A 
0.1% formic acid in water, B  0.1% formic acid in 80%
acetonitrile/20% water) at a flow rate of 200 nL/min.
The LTQ was operated in the positive-ion mode using a
spray voltage of 1.7 kV and a capillary temperature of
220 °C. The MS/MS scanning was performed as an
ion-specific experiment with data-independent scans
for full MS and MS/MS scans of unlabeled and labeled
precursor ions. The instrument settings were 28% nor-
mal collisional energy of the precursor MS ions at m/z
663.5 and 666.5 (doubly charged species [M2H]2)
with an isolation width of 2.5 Daltons. Mass spectra
were collected over an 80-min period.
Gas Chromatography-Mass Spectrometry
As described, 13C6-enrichment in plasma and CSF
leucine, ketoisocaproic acid (KIC), and phenylalanine
were quantified using capillary gas chromatography-
mass spectrometry (GC-MS; Agilent 6890N gas chro-
matograph and Agilent 5973N mass selective detector,
Palo Alto, CA, USA) [16]. Leucine and phenylalanine
were converted to their heptafluorobutyric propyl
ester derivatives; 13C6-leucine (m/z 349 and 355) and
13C6-phenylalanine (m/z 383 and 389) enrichments were
quantified using GC-MS in negative chemical ioniza-
tion mode. In the same plasma samples, KIC was
isolated, the trimethylsilyl quinoxalinol derivative was
formed, and 13C6 enrichment was quantified usingGC-positive chemical ionization-MS and selected ion
monitoring (m/z 275 and 281) [16]. The GC-MS instru-
ment response was calibrated using gravimetric stan-
dards of known isotope enrichment.
Calculation of Labeled Protein Ratio
Percentage labeled A was calculated as the ratio of all
b- and y-tandem MS ion intensities from A*17–28
(m/z  666.5) divided by all b- and y-tandem MS ion
intensities from A17–28 (m/z  663.5). A custom Mi-
crosoft Excel spreadsheet with macros (available upon
request) was used to sum all b- and y-series ion
intensities, calculate the isotope ratios, and plot the
labeled A curves. Specifically, these calculations were
performed by copying the unlabeled and labeled tan-
dem MS spectra signal intensities averaged over the
elution peak directly from Xcalibur into the custom
Excel spreadsheet. The spreadsheet parsed the data to
identify and sum the signal intensities from predicted
unlabeled and labeled b and y ions, and divided labeled
to unlabeled ion intensities to produce a ratio for that
dataset. The ratio was calculated after summing all ion
intensities for labeled and unlabeled tandem MS ions.
Only the M0 (the most abundant for this peptide) and
M6 ions were used for calculations. The labeled ratio for
each dataset and a standard curve were plotted
automatically.
Participants and Sampling
All human studies were approved by the Washington
University Human Studies Committee and the General
Clinical Research Center Advisory Board. Verbal and
written informed consents were obtained from the
participant.
Results
Quantitation of newly synthesized proteins using stable
isotope-labeled amino acids consisted of five basic
steps: (1) Label proteins by application and incorpora-
tion of stable isotope labeled amino acid(s); (2) isolate
and concentrate the protein of interest from other
labeled proteins, by immunoprecipitation or another
method; (3) proteolytically cleave the protein into
smaller peptide fragments; (4) use tandem mass spec-
trometry to quantitate the relative amounts of labeled
and unlabeled peptide fragments; and (5) calculate the
amount of unlabeled and labeled tandem MS ions
(Figure 1).
In Vitro Labeling and Quantitation
We labeled newly synthesized A in vitro by incubat-
ing neuroglioma cells [14] with 13C6-leucine added to
leucine-free media. This stable isotope-labeled amino
acid was chosen because it equilibrates across the
blood– brain barrier quickly by active transport [17], is
17–28
unlabeled.
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safe and non-radioactive. Labeling a protein with
carbon-13 does not significantly change its chemical or
biologic properties because entire organisms have been
grown on pure carbon-13 substrates/media without
any deleterious effect [18]. Stable isotope-labeled
leucine was incorporated into A at amino acid posi-
tions 17 and 34.
Under these in vitro incubation conditions, all
leucine-containing proteins synthesized are labeled.
The protein of interest, A, was isolated and concen-
trated, using immunoprecipitation techniques. In CSF
and neuroglioma cell culture conditions, A is present
in low picomole amounts per milliliter. Immunoprecipi-
tation conditions for unlabeled A were tested and
refined using archived human CSF and cell culture
media. A was immunoprecipitated from samples of
human CSF or cell culture media using an A-specific
monoclonal antibody (m266; provided by Eli Lilly)
covalently linked to cyanogen bromide Sepharose
beads. A was eluted from the antibody–bead complex
using formic acid, and directly identified and charac-
terized using matrix assisted laser desorption ionization
time of flight (MALDI-TOF) mass spectrometry. Mass
spectra for A were similar to previously published
findings [19] (Figure 2a).
Naturally occurring isotopes, including 13C (1.1% of
all carbon), cause a distribution of masses of larger
molecules, including proteins. Because of the size of A
Figure 1. Quantitation by tandem mass spectrometry (MS/MS)
of amino acid stable isotope labeling of newly synthesized pro-
teins: (a) Trypsin fragments of the protein are separated and
concentrated using liquid chromatography before MS for detec-
tion and quantification of both labeled and unlabeled fragments
using MS/MS ions. (b) Diagram of quantitation of labeled and
unlabeled A and graph of labeling curve to calculate synthe-17–28
sis and clearance rates of proteins.Figure 2. MALDI-TOF qualitative analysis of A. (a) A pep-
tides were immunoprecipitated from human CSF with the central
domain anti-A antibody, m266, directed against amino acids
13–28. After immunoprecipitation, A was eluted with 100%
formic acid and analyzed on a MALDI-TOF mass spectrometer.
Mass spectral peaks are noted with their corresponding peptide
variants; A38, A39, A40, and A42. The level of A42 was
approximately 10% of A40 levels, as previously reported in
human CSF. (b) Unlabeled media from a human neuroglioma cell
line producing A in vitro was collected and immunoprecipitated.
A peptides were then cleaved with trypsin at sites 5, 16, and 28
producing the two fragment envelopes shown at masses 1325 and
1336. Note the two mass envelopes of A fragments A17–28 (1325)
and A6–16 (1336) showing the statistical distribution of natural
isotopes in unlabeled A. (c) Human neuroglioma cells were
cultured for 24 h in the presence of 13C6-leucine. Media was
collected and Awas immunoprecipitated. A peptides were then
cleaved with trypsin at sites 5, 16, and 28 producing the fragment
envelopes shown at masses 1325, 1331, and 1336. Note the shift of
mass (arrow) of A17–28 from 1325 to 1331 that demonstrates the
13C6-leucine label. A6–16 does not contain a leucine and so is not
labeled or mass shifted. A minor amount of A remains
Figure 3. LCQ quantitation of MS/MS spectra of in vitro unlabeled and labeled A17–28.
(a) Neuroglioma cell media that was unlabeled (top) or labeled (bottom) with 13C6-leucine. The spectra
were obtained using MS/MS analysis of unlabeled parent ion A17–28 (m 1325) or labeled parent ion
A17–28 (m  1331) by LCQ-ESI-MS. Note the tandem MS ions containing leucine at A17 (see masses
213, 360, 921, and 978) are mass shifted by 6 Daltons demonstrating the labeled leucine (arrows). The
A ions without leucine are not labeled and are not mass shifted by 6 Daltons (see mass 348.2 and
405.3 in both spectra). (b) Base peak chromatograms of MS1 versus MS2 quantitation. In the same MS
run after immunoprecipitation and trypsin digestion of A 2.5% leucine-labeled culture was analyzed.
Reconstructed base peak chromatograms demonstrate the signal-to-noise ratio improvements of MS2
versus MS1 quantitation. (c) Standard curve of labeled A to unlabeled A. Labeled cultured media
was serially diluted with unlabeled media to generate samples for a standard curve. A was
immunoprecipitated from the media, trypsin digested, and A17–28 fragments were analyzed on
a LCQ-ESI-MS and the tandem mass spectra ions were quantitated using custom-written software.
The predicted percentage labeled A versus the measured value is shown with a linear regression
line.
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A was enzymatically cleaved into fragments (A1–5,
A6–16, A17–28, and A29–40/42) using trypsin, before
mass spectrometry analysis. The A17–28 fragment has a
nominal mass of 1324.6 Daltons (D), contains one
leucine residue, and was detected using MALDI-TOF-
MS, as a singly charged species at m/z 1325.6 [MH]1.
The A6–16 fragment has a nominal mass of 1335.7 D,
does not contain a leucine residue, and was detected as
a singly charged species at m/z 1336.7 D [MH]1.
MALDI-TOF-MS analysis identified the A17–28 peptide
fragment in tryptic digests of A isolated from cells
grown in the presence of naturally abundant 13C-
leucine (Figure 2b) and from cells grown in the presence
of 13C6-leucine (Figure 2c). This confirmed that neuro-
glioma cells incorporated 13C6-leucine into the pre-
dicted A fragment, resulting in the expected 6 D shift
in A17–28 peptide, and that this high level of
13C6-
leucine incorporation could be easily detected using
MALDI-TOF-MS. This confirmed the specificity of the
immunoprecipitation techniques in CSF and cell media
and the ability to qualitatively identify labeled and
unlabeled A peptides.
After the isolation and detection of labeled and
unlabeled A, the amount of labeled and unlabeled
A17–28 peptides was quantified using LC-ESI-tandem
MS with quantitation of the full-scan tandem MS ions.
The product ions detected by tandem mass spectrome-
try specifically identified the amino acid sequence for
the labeled peptides based on the signature mass plus
6 D. This provided a highly specific “fingerprint” of the
A17–28 in both labeled and unlabeled forms. The tan-
dem MS confirmed the expected amino acid sequence
for A17–28, and the mass spectra signal intensities were
used to quantify the amount of labeled/unlabeled
leucine in A17–28 (Figure 3a).
Calculation of the Ratio of Labeled
to Unlabeled Peptide
To assess the ratio of labeled to unlabeled A, the signal
intensities from the product ions obtained in the tan-
dem MS experiments were used to quantify the ratio of
labeled to unlabeled A17–28. The tandem MS spectra
were averaged over the time that A eluted from the LC
column (number of tandem MS scans  5) for both
labeled and unlabeled tandem MS spectra. Each aver-
age intensity measurement was exported to an Excel
spreadsheet where the masses of the expected A
tandem MS ions were matched and the tandem MS ion
signal intensities were summed. The labeled/unlabeled
ratio was derived by dividing the total tandem MS ion
intensities, detected in the labeled spectra, by the total
tandem MS ion intensities, in the unlabeled spectra,
using a custom-written Microsoft Excel spreadsheet.
Accuracy and precision were tested by generating a
standard curve from serial dilutions of 13C6-leucine
labeled and unlabeled A formed in vitro (Figure 3c).The linear fit, from a range of 0 to 20% labeled A serial
dilution standard curve, had an R2 value of 0.98 and
slope of 1.08. Alternative quantitation techniques were
evaluated, and included, using the parent ion-signal
intensities and the MALDI-TOF-MS spectra signal in-
tensities. However, the sensitivity and specificity of
these quantitative methods were inferior to those
achieved using the signal intensities of tandem MS
product ions. Specifically, labeled precursor ions were
difficult to detect in the TIC or base peak MS scans
above baseline noise (Figure 3b) and produce erroneous
values (10% for a 2.5% labeled standard). However,
they were easily detected and their signal intensities
were quantified by tandem MS analysis (Figure 3). We
concluded that A can be labeled in vitro, and the
amount of labeling can be quantitated accurately and
precisely using LC-ESI-tandem MS.
In Vivo Labeling and Quantitation
Ten young, healthy human volunteers were enrolled in
a metabolism study of A kinetics to determine the
production and clearance rate of A [13]. The results
indicate that this novel technique provided plausible in
vivo A protein production and clearance rates. We
further validate the in vivo method by quantifying two
A production rates and a clearance rate in a middle-
aged (40–60 years old) healthy research participant
during a 13C6-leucine infusion, followed by the infusion
of a second stable isotope-labeled amino acid (13C6-
phenylalanine) in the same participant. We hypothe-
sized that both tracers would provide similar estimates
for in vivo A production rates. We intravenously
administered a primed (2 mg/kg bolus over 10 min)
constant 13C6-leucine (2 mg kg
1 h1) infusion for the
first 9 h of the study, stopped the 13C6-leucine infusion
at 9 h, and intravenously administered a primed (3mg/kg
bolus over 10 min), constant 13C6-phenylalanine (3 mg
kg1 h1) infusion from 16 to 25 h. CSF samples (6 mL)
were obtained from an indwelling lumbar catheter every
hour from 0 to 36 h.
We used GC-MS to quantify 13C6 precursor amino
acid enrichment in several accessible pools; CSF 13C6-
leucine and 13C6-phenylalanine, plasma
13C6-leucine,
13C6-KIC, and
13C6-phenylalanine. The labeled amino
acid ratio was calculated as the average of the CSF
labeled to unlabeled ratio amino acid as measured by
GC-MS over the hours during infusion (hours 1 to 9 for
leucine and hours 17 to 25 for phenylalanine). The
average labeled CSF leucine  11.5%, plasma leucine 
16.4%, plasma KIC  12.7%, CSF phenylalanine 
22.3%, and plasma phenylalanine  26.9%.
A was immunoprecipitated from CSF, digested
with trypsin, and 13C6-leucine and
13C6-phenylalanine
abundances in A17–28 were detected and quantified
without significant interference (Figure 4a and b).
The calculated A FSRs were similar, accounting for
the twofold higher 13C6-phenylalanine enrichment
in the CSF precursor during the infusion and the
Figure 4. LTQ quantitation of tandem mass spectra of A from human in vivo labeling with two
amino acids. (a) Tandem MS spectra of A17–28 from human CSF 13 h after in vivo
13C6-leucine
labeling demonstrate unlabeled A17–28 tandem MS ions (top) and labeled A17–28 tandem MS ions
(bottom). The leucine containing tandem MS ions demonstrate the additional six Dalton label, as
shown by arrows to leucine-containing ions. (b) Tandem MS spectra of A17–28 from human CSF 12 h
after in vivo labeling with 13C -phenylalanine demonstrate unlabeled ions (top), singly labeled ions6
(middle), and doubly labeled ions (bottom), as shown by arrows to phenylalanine-containing ions.
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poration into A17–28 versus time curves compared to
leucine. The A FSR was 4.8%/h as measured by
13C6-leucine–labeled A and 5.8%/h from
13C6-
phenylalanine–labeled A (Figure 5). The A FCR
was 3.9%/h as measured by 13C6-leucine–labeled A
and could not be measured from 13C6-phenylalanine–
Figure 5. Two sequential measurements of fractional synthesis
rate of A in the same participant. The ratio of labeled A to
unlabeled A over 36 h is shown for a single participant who was
intravenously given 13C6-leucine for 0 to 9 h, followed by phenyl-
alanine given from 16 to 25 h of the study. Cerebrospinal fluid was
collected hourly during and after labeling for a total of 36 h. Each
hourly sample was immunoprecipitated for A, trypsin digested,
and analyzed for percentage leucine- and phenylalanine-labeled
A. Note the rapid increase in leucine-labeled A to plateau at
12 h and a subsequent decline in labeled A after 24 h. There is no
detectable phenylalanine labeling until hour 20, followed by a
rapid rise to plateau. (a) A17–28 labeled leucine tandem MS ions
were quantified excluding 13C6-phenylalanine–containing ions
and plotted over 36 h. Leucine-labeled ions are detected 5 h after
onset of labeling. FSR was calculated using the slope of the linear
regression shown divided by the 13C6-leucine enrichment in CSF.
(b) 13C6-phenylalanine–labeled A17–28 tandem MS ions were
quantified excluding 13C6-leucine–containing ions and plotted
over 36 h from the same tandem MS data files as in (a). There are
no detectable phenylalanine-labeled ions during peak leucine-
labeled A times (5–20 h). Phenylalanine-labeled ions are detected
5 h after onset of 13C6-phenylalanine labeling. FSR was calculated
using the slope of the linear regression shown divided by the
13C6-phenylalanine enrichment in CSF.labeled A because of only 36 h of sampling.Discussion
We describe a method to quantify low-level stable
isotope-labeled amino acid incorporation into a low-
abundance (fmol) cerebrospinal fluid protein (A),
based on immunoprecipitation of the protein and tan-
dem MS to quantify the abundance of 13C-labeled
amino acid residues in tryptic peptides. This novel
technique has been used to quantify human A produc-
tion and clearance rates. The technique is reproducible
because two different stable isotope-labeled amino ac-
ids provided similar estimates of human A production
rates. The technique can be adapted to simultaneously
quantify any/several proteins produced and degraded
in vitro or in vivo systems. The technique is robust
because it can be used to quantify production and
clearance for any protein that can be isolated (not
necessarily to purity) from a biological fluid and pro-
vides the advantage of confirming the protein/peptide
identity because the amino acid sequence is derived
from the tandem MS ions. Most important, perhaps,
this in vivo approach can be used to quantify alterations
in low-abundance protein production and clearance
rates that may underlie the pathogenesis of human
disease, to identify and quantify potential biomarkers
for disease, and to evaluate the efficacy of proposed
disease-modifying therapies. Potentially, this general
approach can be applied to quantify the kinetics of
other macromolecules produced in the CNS, including
lipids, carbohydrates, and inflammatory markers, al-
though care must be taken to select an appropriate
stable isotope-labeled precursor that crosses the blood–
brain barrier and does not enter rapidly recycling
metabolic processes. In addition, the method may pro-
vide quantitative and comparative kinetic information
about proteins that exist in multiple accessible compart-
ments (blood, CSF, or urine).
Established stable isotope tracer methods and mass
spectrometric analytical approaches exist (GC-MS and
gas isotope ratio MS) for quantifying the in vivo syn-
thesis and clearance rates for abundant (microgram to
milligram quantities) proteins, such as albumin, apoli-
poprotein B, myosin, and surfactant [11, 20 –24]. Newer
methods using SDS-PAGE and MALDI-TOF can quan-
tify multiple in vivo protein synthesis and clearance
rates [25] or in vitro prokaryotic synthesis to degrada-
tion ratios [26]. These advances have helped automate
and extend the capabilities for quantitative proteomics.
Although accurate, these methods were not suitable for
a low-abundance (fmol) protein such as A. We have
exploited the recent advances in LC-ESI-tandem MS to
further refine these methods so that sensitive, specific,
accurate (1%), and reliable quantitation of stable iso-
tope abundance in isolates of very low abundance
proteins/peptides (fmol) can be achieved. The SILT
approach demonstrates significantly higher sensitivity
for total amount of protein (fmol), percentage labeling
(accurate to within 1% on a single analysis), and auto-
mation by using LC-MS/MS without the need for
1005J Am Soc Mass Spectrom 2007, 18, 997–1006 ISOTOPE-LABELED PROTEIN MS2 QUANTITATIONprotein separation by gel electrophoresis. We demon-
strate this proof-of-principle by quantifying the in vivo
kinetic rates for a biologically relevant protein that is
involved in the pathogenesis of AD. Another advantage
of this approach is that during the stable isotope label-
ing experiment, any/all proteins that are being pro-
duced are labeled simultaneously. This approach and
quantitative mass spectrometry provide the potential to
simultaneously quantify multiple protein production
and clearance rates in the same samples by measuring
percentage labeling of many peptides using SILT anal-
ysis. The only requirements are that at least one peptide
with a potential labeled amino acid is quantified. For
the A peptide detected in this study, the labeled
leucine was located on the N-terminus, and thus all
b-ions were labeled and y-ions were unlabeled. Because
the phenylalanine residues were located in central po-
sitions, some b- and some y-ions were labeled, whereas
others were unlabeled. The SILT algorithm separately
summed labeled MS2 ions (those containing the amino
acid that could potentially be labeled) and unlabeled
MS2 ions before calculating the ratio. The labeling can
occur at any position and, after the peptide sequence is
determined from the tandem MS spectra, the MS2 ions
that are expected to be labeled, and thus mass shifted,
are predicted from the sequence and can be used in the
calculation of labeled to unlabeled ratio. The measure-
ment and calculation are not dependent on amino acid
location in the peptide sequence.
We chose to use the CSF 13C6-leucine and
13C6-
phenylalanine enrichment to represent the precursor
pool enrichment for A synthesis in our analysis based
on several facts. CSF is within the central nervous
system, and should reflect brain tissue extracellular
enrichment better than plasma. Also, the CSF 13C6-
leucine enrichment was similar to plasma 13C6-KIC
enrichment and KIC likely reflects the intracellular pool
enrichment better than plasma leucine. Because there
are two phenylalanine residues in the A peptide
fragment analyzed, an elegant precursor enrichment
measurement, mass isotopomer distribution analysis
(MIDA), may theoretically be used to measure the
precursor enrichment directly [27]. However, because
there is only one leucine present in this peptide frag-
ment, MIDA could not be used with the leucine tracer
and would not be suitable for comparison of leucine
and phenylalanine precursor enrichments.
Protein quantitation using tandem MS is well estab-
lished based on extracted ion chromatograms, which
quantitate the MS parent ions, as opposed to the MS2
ions used in this study [28]. Using MS precursor ions for
quantitation, a change of 30 to 50% in protein amounts
can be detected. The tandem MS analysis used here is
different because it strongly suggests that LC-ESI-
tandem MS can provide very sensitive (1%) and
accurate (1% SD) quantitation of stable isotope enrich-
ment (isotope ratios) in very low abundant proteins/
peptides. The minimum level of protein we have
analyzed by SILT has been 33 fmol A before immuno-precipitation and trypsin digest with a sensitivity of 1%
labeling and a linear fit of the standard curve with an
R2  0.99. This level of sensitivity was not possible
through use of precursor MS1 quantitation. For exam-
ple, the labeled A could not be detected above baseline
in the MS1 scan (Figure 3b). Among other reasons, this
is possible because we quantified the tandem MS signal
intensities for b- and y-series ions, for both the labeled
and unlabeled A17–28 peptide. This “summing” of the
tandem MS ion signal intensities effectively increased
both the sensitivity and specificity of the isotope ratio
quantitation.
Conclusion
SILT offers a way to measure protein isotope ratios in
vitro and in vivo for a large number of proteins that
were previously too low in abundance for quantitative
isotope abundance analysis. The technique may be
applied for total protein quantitation using stable iso-
tope labeled standards or for isotope ratios in determin-
ing protein production and clearance rates. This may
lead to new information about the physiology and
pathophysiology of biologically and medically relevant
proteins or other macromolecules.
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